Send to

Choose Destination
Shock. 1997 Jun;7(6):391-404.

Platelet-activating factor (PAF) in experimental and clinical sepsis.

Author information

Department of Surgery, Thomas Jefferson University, Jefferson Medical College, Philadelphia, Pennsylvania 19107, USA.


Despite considerable progress in understanding the pathogenic mechanisms of Gram-negative sepsis, the outcome of septic patients has not significantly improved. There are ample data that support a role for inflammatory mediators in sepsis that act in synergy with infectious agents to initiate and propagate the disease process. One such mediator is the glycerophospholipid platelet-activating factor (PAF). The objective of the present review is to summarize experimental and clinical evidence implicating PAF as a mediator in the pathomechanism of sepsis. This review is timely because many potent and selective PAF antagonists have matured for clinical development and a careful analysis of the data that support or refute the merit of clinical trials with such compounds may be important for both academic and pharmaceutical applications.

[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center